Citigroup’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,200
| Closed | -$22K | – | 7764 |
|
|
2020
Q2 | $22K | Sell |
1,200
-1,000
| -45% | -$13.9K | ﹤0.01% | 6564 |
|
|
2020
Q1 | $16K | Sell |
2,200
-9,200
| -81% | -$115K | ﹤0.01% | 6839 |
|
|
2019
Q4 | $272K | Buy |
11,400
+6,000
| +111% | +$166K | ﹤0.01% | 4926 |
|
|
2019
Q3 | $145K | Sell |
5,400
-3,100
| -36% | -$87K | ﹤0.01% | 5410 |
|
|
2019
Q2 | $231K | Sell |
8,500
-2,600
| -23% | -$81.5K | ﹤0.01% | 5133 |
|
|
2019
Q1 | $385K | Sell |
11,100
-8,900
| -45% | -$257K | ﹤0.01% | 4467 |
|
|
2018
Q4 | $390K | Buy |
20,000
+12,200
| +156% | +$251K | ﹤0.01% | 4392 |
|
|
2018
Q3 | $208K | Sell |
7,800
-32,100
| -80% | -$1.05M | ﹤0.01% | 5216 |
|
|
2018
Q2 | $1.51M | Buy |
39,900
+18,700
| +88% | +$715K | ﹤0.01% | 2949 |
|
|
2018
Q1 | $692K | Sell |
21,200
-20,700
| -49% | -$908K | ﹤0.01% | 3640 |
|
|
2017
Q4 | $2.04M | Buy |
41,900
+3,700
| +10% | +$187K | ﹤0.01% | 2655 |
|
|
2017
Q3 | $2.06M | Buy |
38,200
+8,600
| +29% | +$505K | ﹤0.01% | 2624 |
|
|
2017
Q2 | $1.66M | Sell |
29,600
-1,400
| -5% | -$56.1K | ﹤0.01% | 2779 |
|
|
2017
Q1 | $1.22M | Sell |
31,000
-500
| -2% | -$15.9K | ﹤0.01% | 3012 |
|
|
2016
Q4 | $707K | Buy |
31,500
+24,200
| +332% | +$473K | ﹤0.01% | 4031 |
|
|
2016
Q3 | $166K | Buy |
+7,300
| New | +$171K | ﹤0.01% | 4809 |
|
Citigroup's PTLA Position: Q3 2020 in Review
Citigroup sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,770,806 shares — an estimated $31.9M sold.
Citigroup first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $41.4M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citigroup reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citigroup sold 1,770,806 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $31.9M.
- Citigroup first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Citigroup's Portola Pharmaceuticals, Inc. position peaked at $41.4M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citigroup's 13F filing for Q3 2020, filed 12 Nov 2020.